Provided is a cardiovascular implant based on in-situ regulation of immune response and a method for making the same, belonging to the technical field of biomedicine. The cardiovascular implant includes a cardiovascular implant body and H4000-CD25/dcas9 sustained-release nanoparticles modified on the cardiovascular implant body; the H4000-CD25/dcas9 sustained-release nanoparticles include an H4000 plasmid nanocarrier (Engreen), an anti-CD25 antibody, and a dcas9 plasmid sequence; a method for preparing the cardiovascular implant includes: constructing a cardiovascular implant body, preparing an H4000-CD25 nanotransfection vector, preparing H4000-CD25/dcas9 sustained-release nanoparticles, and conjugating the H4000-CD25/dcas9 sustained-release nanoparticles on the cardiovascular implant body. The present disclosure aims to construct a cardiovascular implant modified with the H4000-CD25/dcas9 sustained-release nanoparticles, which may induce nerve fiber ingrowth into engineered blood vessels; with the regulation ability of Treg cells on immune response, antithrombotic function of the cardiovascular implant is improved and in-situ regeneration of the cardiovascular implant is promoted.

Medical devices and methods for delivering fluid. The medical devices include one or more needles for delivering fluid. The methods may optionally include expanding an expandable member such as an inflatable member to expand an expandable scaffold outward toward a lumen wall. The devices may include one or both of one or more spine securing members or one or more needle alignment members.

Medical devices and methods for delivering fluid. The medical devices include one or more needles for delivering fluid. The methods may optionally include expanding an expandable member such as an inflatable member to expand an expandable scaffold outward toward a lumen wall. The devices may include one or both of one or more spine securing members or one or more needle alignment members.

Methods for forming micro- and/or nano-structures on the surfaces of a device and devices made thereby. The methods include exposing the surfaces of the device having an initial microstructure to an oxidizing environment at a first elevated temperature so as to form a first oxide scale on the device surfaces, exposing the first oxide scale to a reducing agent at a second elevated temperature so as to convert or partially convert the first oxide scale into a composite scale that includes a second oxide and a first metal, and exposing the composite scale to a dissolution agent that selectively dissolves part or all of the second oxide so as to yield a porous surface layer that includes the first metal.

Bone-contacting surfaces and free surfaces of orthopedic implants. The implants are additively manufactured, followed by mechanical, chemical, or mechanical and chemical erosion. At least some of the surfaces of the implants include an osteoinducting roughness that has micro-scale structures and nano-scale structures that facilitate and enhance osteoinduction and osteogenesis, as well as enhanced alkaline phosphatase, osterix, and osteocalcin expression levels along the pathway of mesenchymal stem cell differentiation to osteoblasts.

Bone-contacting surfaces and free surfaces of orthopedic implants. The implants are additively manufactured, followed by mechanical, chemical, or mechanical and chemical erosion. At least some of the surfaces of the implants include an osteoinducting roughness that has micro-scale structures and nano-scale structures that facilitate and enhance osteoinduction and osteogenesis, as well as enhanced alkaline phosphatase, osterix, and osteocalcin expression levels along the pathway of mesenchymal stem cell differentiation to osteoblasts.

This document describes a process of producing gel microparticles, which are consistent in size and morphology. Through the process of coacervation, large volumes of gel microparticle slurry can be produced by scaling up reactor vessel size. Particles can be repeatedly dehydrated and rehydrated in accordance to their environment, allowing for the storage of particles in a non-solvent such as ethanol. Gel slurries exhibit a Bingham plastic behavior in which the slurry behaves as a solid at shear stresses that are below a critical value. Upon reaching the critical shear stress, the slurry undergoes a rapid decrease in viscosity and behaves as a liquid. The rheological behavior of these slurries can be adjusted by changing the compaction processes such as centrifugation force to alter the yield-stress. The narrower distribution and reduced size of these particles allows for an increase in FRESH printing fidelity.

An alloy for biomedical use includes Zr as a main component, Nb the content of which is not less than 0.1% by weight and not greater than 25% by weight, Mo the content of which is not less than 0.1% by weight and not greater than 25% by weight, and Ta the content of which is not less than 0.1% by weight and not greater than 25% by weight. A tensile strength of the alloy is not less than 1000 MPa. A total content of Nb, Mo, and Ta in the alloy is not less than 2% by weight and not greater than 50% by weight. Mass susceptibility of the alloy is not greater than 1.50×10.sup.−6 cm.sup.3/g. A Young's modulus of the alloy is not greater than 100 GPa. Also disclosed is a medical product including the alloy and a method for producing the alloy.

The invention provides a thermosensitive peptide hydrogel, which comprises water, a polyether/polyol polymer and a peptide molecule. The peptide molecule has a structure represented by the following chemical formula (1). Chemical Structure (1): ##STR00001##

The invention provides a thermosensitive peptide hydrogel, which comprises water, a polyether/polyol polymer and a peptide molecule. The peptide molecule has a structure represented by the following chemical formula (1). Chemical Structure (1): ##STR00001##